JGC
IMPL

J. Goldman & Co’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

J. Goldman & Co’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-49,569
Closed -$63K – 524
2023
Q2 		$63K Sell
49,569
-30,650
-38% -$46.5K ﹤0.01% 352
2023
Q1 		$112K Sell
80,219
-120,000
-60% -$286K ﹤0.01% 329
2022
Q4 		$751K Buy
+200,219
New +$730K 0.04% 242

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

J. Goldman & Co's IMPL Position: Q3 2023 in Review

J. Goldman & Co sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2023, closing a stake of 49,569 shares — an estimated $63K sold.

J. Goldman & Co first reported a position in IMPL in Q4 2022 and held it in 3 quarters. The position peaked at $751K in Q4 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q3 2023.

  • J. Goldman & Co reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • J. Goldman & Co sold 49,569 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $63K.
  • J. Goldman & Co first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • J. Goldman & Co's Impel Pharmaceuticals Inc. Common Stock position peaked at $751K in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.